When asked about proportionate stakeholder responsibility – payer, provider, patient, pharmacy – in developing a value-based algorithm in healthcare, is there a singular answer? The short answer, single payer system notwithstanding, is that all stakeholders must share responsibility on cost-versus-cure decision points.
A more revealing pair of questions to ask is how long is going to take the needed parties to engage in non-threatening, meaningful conversation to create solutions and who leads that discussion?
True alignment among stakeholders is one of the most pressing issues facing our healthcare system today. In order to experience widespread benefit from the 3,400 cancer immunotherapies ongoing in the U.S. today, we must have meaningful discussions about the value of care, including pharmaceutical therapies, and the value of life. All parties must be at the table to ensure actionable dialogue about value and the allocation of scare resources.
Resource discussions are never easy, and they are even less so when the issue at hand is determining the value of life, or the value of the extension of life. In theory, allocation is determined based on the value placed on every element that serves or receives services from each stakeholder. However, US healthcare policy makers have yet to weigh in with figures.
That said each set of stakeholders should anticipate increased requirements to substantiate value as part of the shifting healthcare landscape.
To read more about what patients, prescribers, manufacturers, payers and PBMs should be prepared to demonstrate as part of the value equation, read Marc’s full article at Specialty Pharmacy Times.
To learn more about Curant Health, contact Kristin Lindsey, Senior Marketing Director, at email@example.com.